Alpha Tau Treats First Brain Cancer Patient Outside US, Expanding Alpha DaRT Reach
DRTS has more than doubled off its 52-week low of $2.87 on light trading volume (0.4× avg).
Summary
Alpha Tau Medical successfully treated its first glioblastoma patient outside the U.S. with its Alpha DaRT therapy at Hadassah University Medical Center, completing the procedure safely. This follows a 6-K filing yesterday announcing the event and continues a strong run of positive clinical and partnership milestones for the company. The international expansion into brain cancer is significant, demonstrating the therapy's broader applicability for a highly aggressive disease with limited treatment options. This adds to Alpha Tau's growing global clinical footprint.
At the time of this announcement, DRTS was trading at $10.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $900.3M. The 52-week trading range was $2.87 to $11.62. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: FinanceWire.